Pediatric interferon (Beijing Tri-Prime Genetic Engineering)

N/A

Report date: 2022/11/07 19:19:41

Base Information

Drug NamePediatric interferon (Beijing Tri-Prime Genetic Engineering)
Drug Alias Name儿科专用干扰素
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunomodulatorsInterferon alpha/beta receptor agonistsInnate antiviral immune response inducers
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsPneumonia, ViralBronchiolitis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Tri-Prime Gene Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Tri-Prime Gene Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPneumonia, ViralBronchiolitis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A